Cell-Based BoNT Assays for Serotype-Specific FRET Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting botulinum neurotoxins (BoNTs) are inadequate in terms of sensitivity and specificity, particularly in distinguishing between different serotypes, and existing cell-based assays using FRET technology are limited by the lack of serotype-specificity due to native substrate proteins being cleaved by multiple BoNT serotypes.
Innovation Solution
Genetically modified neuroblastoma cell lines expressing a reporting construct that incorporates a peptide substrate specific to both BoNT/A and BoNT/E, allowing for high selectivity and sensitivity to BoNT/A while being less responsive to BoNT/E, achieved through cellular characteristics and functions rather than the reporting construct itself.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional immunoassays or FRET-based cell assays are used to detect BoNTs, then sensitivity and detection capability are improved, but serotype specificity deteriorates because native substrate proteins are cleaved by multiple BoNT serotypes
Solution Approach 1:
The patent introduces serotype-specific properties at the cellular level by expressing different SNARE protein variants (with different cleavage site sequences) in specific cell lines. This allows each cell line to be locally optimized for detecting a particular BoNT serotype while maintaining high sensitivity through the FRET assay mechanism.
Solution Approach 2:
The invention changes the molecular parameters of the substrate proteins by using mutated or variant SNARE proteins with altered cleavage site sequences that are specific to particular BoNT serotypes. This parameter modification enables serotype-specific detection while preserving the overall FRET assay sensitivity.
2Measurement precision
If mouse toxicity assays are used as the gold standard for BoNT detection, then accuracy is improved, but time consumption and ethical concerns increase
Solution Approach 1:
The patent replaces the complex in vivo mouse toxicity assay system with an in vitro cell-based FRET assay system. This substitution maintains detection accuracy by preserving the essential proteolytic cleavage mechanism while eliminating the time-consuming and ethically problematic animal model requirements.
Solution Approach 2:
The invention creates simplified cellular models that copy the essential neurotoxin-protein interaction mechanism from native neuronal cells. These cell lines express human SNARE proteins and exhibit the same cleavage specificity as native neurons, providing an accurate but faster alternative to mouse assays.
3Manufacturing precision
If HPLC separation and immunoassays are used to detect peptide fragments, then specificity is improved, but device complexity and time consumption increase
Solution Approach 1:
The patent extracts only the essential detection function from complex HPLC-immunoassay systems by using cell-based FRET assays that directly report proteolytic activity through fluorescence changes. This eliminates the need for peptide fragmentation, separation, and antibody-based detection steps while maintaining serotype-specificity.
Solution Approach 2:
The invention replaces complex mechanical separation systems (HPLC) and antibody-based detection systems with a simple fluorescence-based readout system. The FRET signal change directly reports proteolytic cleavage events, eliminating multiple processing steps and reducing overall system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified cell lines demonstrate a 100-fold or greater difference in EC50 between BoNT serotypes with the same substrate protein specificity, providing enhanced discrimination and sensitivity to BoNT/A with a limit of detection of 50 fM or less, without the need for serotype-specific antibodies or heavy chain analogs.
Implementation Method 1
Cell based assays based on Forster Resonance Energy Transfer (FRET) measurements of cells carrying reporting peptides incorporated FRET pairs of fluorophores separated by peptides corresponding to the scissile portion of SNARE proteins
Implementation Method 2
In the intact reporting peptide fluorescence signal of one of these fluorescent moieties (i.e., the donor fluorophore) is quenched by the other fluorescent moiety (the acceptor). At the same time an increase in fluorescence is observed from the acceptor fluorophore on excitation of the donor fluorophore.
Implementation Method 3
the light chain is translocated from the endosomal vesicle lumen into the cytosol, and acts as a zinc-dependent protease to cleave proteins that mediate vesicle-target membrane fusion
Data Source
AI summary
Serotype-specific cell based assays for the characterization of Clostridia botulinum neurotoxins and genetically modified cells utilized in such assays are described. Such assays and genetically modified cells can discriminate between different serotypes of clostridium neurotoxins having the same SNARE protein substrate specificity, despite a lack of such discrimination in the parental cell line. This discrimination is achieved without the use of serotype-specific neutralizing antibodies and without the use of competing heavy chains derived from a Clostridia botulinum neurotoxin.